Declining Prices of Sequencing Is Expected to Enhance the Epigenetics Market from 2018 to 2025

Publisher: The Insight Partners

Declining prices of sequencing is expected to enhance the Epigenetics Market from 2018 to 2025.

The global epigenetics market is expected to reach US$ 2,611.57 Mn in 2025 from US$ 991.45 Mn in 2017. The market is estimated to grow with a CAGR of 13.6% from 2018-2025.

The major players operating in the epigenetics market include  Merck KGaA, Thermo Fisher Scientific Inc., ABCAM Plc, Agilent Technologies, Active Motif, QIAGEN, Bio-Rad Laboratories, Inc., Perkinelmer Inc., New England Biolabs (NEB), and Illumina Inc.
The declining costs associated with different strategies and methods for sequencing supports to influence the scale and scope of almost all genomic research projects. The costs associated with DNA sequencing performed at the sequencing centers which is funded by the Institutes, has tracked by the National Human Genome Research Institute (NHGRI) for many years. This information has served as a key standard for establishing the DNA sequencing capacity and considering improvements in DNA sequencing technologies of the NHGRI Genome Sequencing Program (GSP).  In the recent years, next generation sequencing price have declined substantially. For instance, first whole human genome sequencing cost over US$3.7 billion in 2000 and took 13 years for the completion. However, the costs for the same in recent years has reduced to US$1,000 and the process requires less number of days. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Major market players such as Illumina and Roche have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing. Owing to factors such as advances in the field of genomics, development in different methods and strategies for sequencing, there is a notable decline in the cost of sequencing, that upsurge the growth of the market.
In recent years, the demand for cutting edge technology in order to gain high speed results and accuracy is increasing. Technological development has enabled advances in sequencing technology leading to a sharp increase in the cost of sequencing equipment. Companies such as Illumina and PacBio offer instruments with high cost. For instance, Illumina MiSeq cost for US$ 128,000 and PacBio RS cost for US$ 695,000. Thus, the high cost of next generation sequencers is hindering the growth of the market for in the future.

The psychologists are focusing to pioneer the fields of epigenetics and neurogenetics to introduce better therapies and treatment for brain related disorders. The psychologists are putting their efforts that vastly improving the treatments for mental illness and neurodevelopmental disorders such as autism and attention-deficit/hyperactivity disorder (ADHD). For the research and development in this field, many individual institutes such as, the National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism and the National Institute of Mental Health providing generous funding in the epigenetics area. Moreover, in the year 2014 and 2016, the NIDA grants $12 million to each two groups for the research about the link between behavior related to drug abuse and genes. The neurogenetics addresses gene-related phenomena which is related to the brain and central nervous system. Where the epigenetics comprises the opportunity to examine and control the behavioral influences on genetic programming. The epigenetics provide new tools for enabling this work to proceed with unprecedented accuracy. With the new technology, researchers collect specific DNA samples from various sources such as, blood or saliva and brain tissue to observe the DNA sequence and map out in fine detail about the methylation patterns within a particular gene segment or even a single gene.
 

The application segment of the epigenetics market is classified into metabolic diseases, oncology, cardiovascular diseases and other applications. In 2017, the oncology segment held the largest share of 46.2% of the market, by application. Epigenetic modification plays an important role in the development of adult and pediatric cancer. The rate of the cancer is considerably increasing worldwide. For instance, according to the American Cancer Society (ACS), approximately 1.66 million new cancer cases were estimated, in 2015.

The epigenetics offers prodigious potential for the identification of biomarkers that can be used to detect and diagnose cancer in its earliest stages. The initiation of the cancer involves several molecular changes that include epigenetic alterations. The abnormal epigenetic modifications subsidize to tumorigenesis and helps in resistance to cancer therapy by activating oncogenes and deactivating tumor suppressor genes that involved in the immune response. Moreover, it affects the tumor heterogeneity and helps in suppressing the terminal differentiation.

Thus, owing to the above development for therapies for cancer in the market are likely to propel the growth of the epigenetics market by application in the forecast period.